MYCO-002
| Clinical data | |
|---|---|
| Other names | MYCO002 |
| Drug class | Entactogen; Empathogen |
MYCO-002 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders.[1][2][3] It is said to be being developed towards the aim of improving the safety profile of MDMA.[3] The drug is under development by Mydecine.[1][2] It was patented in July 2021 and received breakthrough therapy designation from the Food and Drug Administration (FDA) in November 2021.[1] As of November 2021, MYCO-002 is in the preclinical research for treatment of psychiatric disorders.[1][2] The chemical structure of MYCO-002 does not yet appear to have been disclosed.[1][2]
See also
[edit]References
[edit]- ^ a b c d e "MYCO 002". AdisInsight. 28 November 2021. Retrieved 29 January 2025.
MYCO 002 is an entactogenic MDMA-like compound being developed by Mydecine Innovations for the potential treatment of mental disorders. [...]
- ^ a b c d "Delving into the Latest Updates on MYCO-002 with Synapse". Synapse. 23 January 2025. Retrieved 29 January 2025.
- ^ a b Mydecine Innovations Group (7 April 2021). "Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical". GlobeNewswire News Room. Retrieved 29 January 2025.
The four initial drug candidates include: [...] MYCO - 002 is an entactogenic compound that has been created with the goal of reducing harm and improving the safety profile vs. traditional MDMA.
 | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |